NAD+ Precursors Compared: NMN vs NR vs Niacin vs Tryptophan
Four routes into the same coenzyme, with different entry points, different costs and different evidence. A structured comparison of every NAD+ precursor worth considering.
The Short Answer
NAD+ can be built through three pathways, and the practical choice between precursors is a choice of entry point. Nicotinic acid (niacin) enters through the Preiss-Handler pathway and raises NAD+ effectively at low cost, with flushing as the trade-off. Nicotinamide enters the salvage pathway but requires NAMPT and inhibits sirtuins at high concentrations. NR and NMN bypass NAMPT and are the best-studied for NAD+ elevation without those drawbacks, at considerably higher cost. Tryptophan feeds the de novo pathway, which is metabolically expensive and contributes a minority of total NAD+. For raising blood NAD+ per dollar, niacin is hard to beat. For raising it without flushing or sirtuin inhibition, NR and NMN are the options with human data.
The Three Pathways
Understanding the comparison requires the map. Mammals synthesise NAD+ through three routes that converge on the same molecule.
The de novo pathway builds NAD+ from the amino acid tryptophan through the kynurenine cascade. It takes eight enzymatic steps, is regulated by inflammatory signalling, and contributes a minority of total NAD+ in most tissues. Roughly sixty milligrams of tryptophan is conventionally regarded as equivalent to one milligram of niacin, which is an inefficient exchange rate for a limited essential amino acid with competing uses in protein and serotonin synthesis.
The Preiss-Handler pathway starts from nicotinic acid, which is converted to nicotinic acid mononucleotide by NAPRT, then to nicotinic acid adenine dinucleotide, then amidated to NAD+. NAPRT is not the bottleneck that NAMPT is, which is why nicotinic acid raises NAD+ efficiently.
The salvage pathway recycles nicotinamide released by NAD+-consuming enzymes. NAMPT converts nicotinamide to NMN, and NMNAT enzymes convert NMN to NAD+. This pathway does most of the day-to-day work, and NAMPT is its rate-limiting step. NR and NMN enter downstream of NAMPT, which is the central mechanistic argument for both.
Precursor by Precursor
Nicotinic acid (niacin)
The most cost-effective NAD+ precursor by a wide margin, and the one with decades of clinical use behind it at high doses. It raises NAD+ reliably, including in tissues, and human work has shown it can improve mitochondrial function measures in specific mitochondrial conditions at gram-level doses. The trade-off is the flush: nicotinic acid activates the GPR109A receptor on skin immune cells, producing prostaglandin-mediated vasodilation, warmth and redness that most people find unpleasant. The flush attenuates with continued use. Extended-release formulations reduce it but shift the profile toward hepatic effects, and gram-level doses have a real clinical monitoring requirement, including glucose handling and liver markers. High-dose niacin is a pharmacological intervention, not a casual supplement.
Nicotinamide
Cheap, stable, non-flushing and well absorbed. It raises NAD+ through the salvage pathway, and at ordinary doses it is simply vitamin B3. Two caveats matter at higher doses. It requires NAMPT, so it does not bypass the bottleneck that declines with age. And nicotinamide is a product inhibitor of sirtuins and of PARPs, so at high concentrations it can suppress the very enzymes that NAD+ elevation is meant to support. It also has genuine dermatological evidence behind it in its amide form for skin outcomes, which is a separate and better-supported use case than longevity.
Nicotinamide riboside (NR)
The most extensively studied precursor in human trials. Bypasses NAMPT, does not flush, does not inhibit sirtuins at supplemental doses, raises blood NAD+ by 40 to 90 percent at 250 to 1,000 mg per day. Its weakness is that trials in healthy older adults have repeatedly failed to show changes in muscle NAD+ or in functional endpoints despite clear blood NAD+ increases. It is also chemically unstable and degrades to nicotinamide, so product quality varies.
Nicotinamide mononucleotide (NMN)
One step closer to NAD+ than NR, with a growing but smaller human literature. Raises blood NAD+ at 250 to 900 mg per day, with modest functional results in metabolically compromised populations. Regulatory status in the United States is unresolved, which affects availability and quality control. Whether NMN is imported intact or dephosphorylated to NR at the cell surface remains debated, and if the latter dominates, the practical distinction from NR is small.
Tryptophan
Not a sensible primary NAD+ strategy. The conversion is inefficient, competes with protein and serotonin synthesis, and is diverted by inflammatory signalling through IDO activation, which is precisely the state in which more NAD+ would be useful. Adequate protein intake covers the de novo contribution. Supplementing tryptophan for NAD+ is solving the wrong problem.
Side-by-Side Comparison
| Precursor | Pathway | Bypasses NAMPT | Trial dose range | Main drawback | Relative cost |
|---|---|---|---|---|---|
| Nicotinic acid | Preiss-Handler | Yes | 50 mg to 2 g/day | Flushing; monitoring needed at high dose | Very low |
| Nicotinamide | Salvage | No | 250 mg to 1 g/day | Sirtuin and PARP inhibition at high dose | Very low |
| NR | Salvage (downstream) | Yes | 250 mg to 1 g/day | Null functional results in healthy adults; unstable | High |
| NMN | Salvage (downstream) | Yes | 250 mg to 900 mg/day | Smaller literature; unsettled regulatory status | High |
| Tryptophan | De novo | Not applicable | Dietary intake | Inefficient conversion; competing uses | Low |
The Question Nobody Answers Clearly
All five precursors raise NAD+ somewhere. The unresolved question is whether raising blood NAD+ produces the outcomes people are buying.
Two findings should temper enthusiasm. First, trials measuring muscle NAD+ directly after NR supplementation have often found no increase, despite large increases in blood. Tissue distribution is not uniform, and blood is the easiest thing to measure rather than the most relevant. Second, the functional trials in healthy adults have largely been null, with the positive signals concentrated in populations starting from a compromised baseline.
That pattern suggests NAD+ repletion behaves more like correcting an inadequate state than like enhancing a normal one. If true, the implication for a healthy adult is that the marginal value is small, and the implication for someone with a genuine metabolic or mitochondrial constraint is that it may be meaningful. Which is a very different proposition from the one the category is marketed on.
Consumption Side: The Underrated Half
Every discussion of NAD+ focuses on synthesis. Levels are set by synthesis minus consumption, and the consumption side is where the age-related decline largely originates.
Three consumers dominate. CD38, an enzyme on immune cells whose activity rises with inflammatory signalling and with age, is a major NAD+ sink. PARP enzymes consume NAD+ in response to DNA strand breaks, so anything that increases DNA damage, including ultraviolet exposure and chronic inflammatory load, increases NAD+ consumption. Sirtuins consume it too, though that is the intended use.
The practical implication is that reducing inflammatory load, managing ultraviolet exposure, sleeping adequately and maintaining aerobic fitness all act on the consumption side, and exercise in particular raises NAMPT expression in muscle. A person spending significant money on precursors while ignoring the consumption side has the arithmetic backwards.
Choosing, and When to Revisit
A structured way to think about the choice, without pretending the evidence supports more precision than it does:
- Cost-sensitive and flush-tolerant: nicotinic acid at low doses, with the understanding that gram-level dosing requires clinical oversight.
- Wanting the deepest human safety record: NR, with realistic expectations about functional outcomes.
- Wanting the most direct salvage entry: NMN, accepting a smaller literature and variable product quality.
- Wanting the best evidence-to-cost ratio overall: address the consumption side first, then decide whether a precursor is still worth adding.
The review trigger for this whole category is external rather than internal. Nobody can feel their NAD+ status. The sensible reassessment point is the publication of larger, longer human trials with functional endpoints, several of which are running now, plus any change in personal context that shifts the underlying reasoning.
The AEONNN Perspective
Stack Builder handles NAD+ precursors as a single functional slot rather than as five separate candidates, which prevents one of the most common stacking errors: taking NMN, NR and a B-complex containing nicotinamide simultaneously and paying three times to fill one node.
The Pharmacokinetics and Safety layers carry more weight here than the Evidence layer, because the compounds differ less in what they achieve than in how they achieve it and at what cost. Nicotinic acid at gram doses is a monitoring question. Nicotinamide at high doses is a sirtuin inhibition question. NR is a product-quality question. The Regulatory layer matters for NMN specifically, and differs by market.
The consumption side is where the Pillar Matrix earns its structure. NAD+ status is not only a Cellular Energy question; inflammatory load sits in Pillar 3, sleep in Pillar 9, and metabolic health in Pillar 4, and all three affect NAD+ consumption. A recommendation engine that only reasons compound-by-compound cannot see that. One that reasons across Pillars can tell a member that their most valuable NAD+ intervention this quarter is not a capsule.
Pillar Matrix mapping
Cellular Energy and Repair, Metabolic and Cardiovascular Health, Longevity and Biological Age
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Mechanistic Layer (KEGG, Reactome, UniProt)
- Pharmacokinetics Layer (HMDB, PubChem)
- Safety Layer (DrugBank, FAERS)
- Regulatory Layer (EFSA, FDA, EMA)
Frequently Asked
Which NAD+ precursor is best?
No precursor has been shown superior for functional outcomes in humans. Nicotinic acid raises NAD+ most cost-effectively but causes flushing. NR has the deepest safety record. NMN sits closest to NAD+ in the pathway. The choice is driven by tolerability, cost and product quality rather than by demonstrated superiority.
Can I take NMN and NR together?
There is no evidence that combining them produces more benefit than an equivalent dose of either alone, since both converge on the same pathway node. It generally means paying twice to fill one slot.
Is niacin as good as NMN for raising NAD+?
Nicotinic acid raises NAD+ effectively, including in some tissues where NR has failed to show increases, and costs a fraction as much. The flush is the main obstacle, and gram-level doses require clinical monitoring of glucose handling and liver markers.
Why does nicotinamide inhibit sirtuins?
Nicotinamide is a product of the sirtuin reaction, and like many product molecules it inhibits the enzyme that generates it when concentrations rise. This is a concern at high supplemental doses rather than at ordinary vitamin intakes.
Does raising blood NAD+ raise it in muscle?
Not reliably. Several controlled trials found no increase in muscle NAD+ content after NR supplementation despite substantial increases in blood. Tissue distribution is uneven, and blood is the convenient measurement rather than the relevant one.
Can NAD+ levels be tested?
Whole blood and intracellular NAD+ assays exist and are used in research, and some consumer services offer them. Interpretation is limited because reference ranges are not well established and blood NAD+ may not reflect the tissue that matters for a given goal.
What raises NAD+ without supplements?
Exercise increases NAMPT expression in muscle. Reducing inflammatory load lowers CD38-driven consumption. Managing ultraviolet exposure and sleeping adequately reduce PARP-driven consumption. These act on the consumption side, which is where much of the age-related decline originates.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.